As previously reported, patients with DLBCL of non‐GCB origin were more likely to respond to Pola‐BR than those of GCB origin in the entire cohort and in second‐line and third‐line setting, albeit lacking statistical significance (Table 7).40 This evidence concerns the gene POLA1 and diffuse large B-cell lymphoma.